Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 52 entries
View as:

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00883116 Org: User:
Start: 08/31/09 End: 02/28/14 Due: 02/28/15

Study of Efficacy of Different Treatment Regimens of Olokizumab

Phase: N/A Priority: Normal
NCT ID: NCT05187793 Org: User:
Start: 07/08/21 End: 04/30/23 Due: 04/30/24

Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence

Phase: N/A Priority: Normal
NCT ID: NCT03663374 Org: User:
Start: 11/18/14 End: 05/14/16 Due: 05/14/17

Ixabepilone Administered as an Enteric Coated Formulation.

Phase: N/A Priority: Normal
NCT ID: NCT00309049 Org: User:
Start: 04/30/06 End: 05/31/07 Due: 05/31/08

Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04501783 Org: User:
Start: 05/20/20 End: 08/04/20 Due: 08/04/21

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00383149 Org: User:
Start: 01/31/07 End: 06/30/09 Due: 06/30/10

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Phase: N/A Priority: Normal
NCT ID: NCT03659305 Org: User:
Start: 07/10/18 End: 01/26/19 Due: 01/26/20

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Phase: N/A Priority: Normal
NCT ID: NCT04246723 Org: User:
Start: 05/06/19 End: 08/12/20 Due: 08/12/21

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04760730 Org: User:
Start: 07/13/21 End: 07/26/22 Due: 07/26/23

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02248961 Org: User:
Start: 05/31/14 End: 08/31/15 Due: 08/31/16

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00634088 Org: User:
Start: 06/30/08 End: 06/30/10 Due: 06/30/11

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00082433 Org: User:
Start: 11/30/03 End: 03/31/08 Due: 03/31/09

A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

Phase: N/A Priority: Normal
NCT ID: NCT01027208 Org: User:
Start: 12/31/06 End: 01/31/07 Due: 01/31/08

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00490646 Org: User:
Start: 02/29/08 End: 11/30/11 Due: 11/30/12

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06307093 Org: User:
Start: 03/01/23 End: 07/31/25 Due: 07/31/26

A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00035516 Org: User:
Start: 02/28/01 End: 04/30/04 Due: 04/30/05

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04684446 Org: User:
Start: 09/15/21 End: 03/29/22 Due: 03/29/23

Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

Phase: N/A Priority: Normal
NCT ID: NCT03551210 Org: User:
Start: 05/04/16 End: 12/26/17 Due: 12/26/18

BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00004927 Org: User:
Start: 07/31/99 End: 10/31/02 Due: 10/31/03

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00546364 Org: User:
Start: 02/29/08 End: 03/31/10 Due: 03/31/11

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01018966 Org: User:
Start: 04/30/04 End: 04/30/05 Due: 04/30/06

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

Phase: N/A Priority: Normal
NCT ID: NCT04067492 Org: User:
Start: 03/26/18 End: 05/12/20 Due: 05/12/21

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00633464 Org: User:
Start: 06/30/08 End: 05/31/11 Due: 05/31/12

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00723957 Org: User:
Start: 12/31/08 End: 08/31/11 Due: 08/31/12

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

Phase: N/A Priority: Normal
NCT ID: NCT03833362 Org: User:
Start: 05/07/14 End: 02/21/17 Due: 02/21/18